🔎 Trials Near Me

Akèy › Leksemi mieloïd egi › Virginia › Arlington

Etid klinik pou Leksemi mieloïd egi nan Arlington, VA

8 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Arlington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Ap rekriteFaz 2
  • Inova Fairfax Hospital, Falls Church · 4 mi lwen
  • Inova Schar Cancer Institute, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT05564390

Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

Ap rekriteFaz 1
  • NEXT Oncology Virginia, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07723703

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • Inova Fairfax Hospital, Falls Church · 4 mi lwen
  • Inova Schar Cancer Institute, Fairfax · 11 mi lwen
Laj 18 a 59 · Tout sèks · Mizajou Sep 28, 2026 · NCT05554393

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • Inova Fairfax Hospital, Falls Church · 4 mi lwen
  • Inova Schar Cancer Institute, Fairfax · 11 mi lwen
Laj 18 a 59 · Tout sèks · Mizajou Sep 22, 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Ap rekriteFaz 3
  • Inova Fairfax Hospital, Falls Church · 4 mi lwen
6 Months – 21 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT04293562

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Ap rekriteFaz 3
  • Virginia Cancer Specialists, Manassas · 22 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07007312

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Ap rekriteFaz 1/2
  • Virginia Cancer Specialists, Fairfax · 11 mi lwen
Laj 12 ak plis · Tout sèks · Mizajou Mar 24, 2026 · NCT04988555

Etid Leksemi mieloïd egi nan lòt vil

Lòt etid nan Arlington

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.